Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers
Natural killer (NK) cells are potent antitumor effectors, involved in hematological malignancies and solid tumor immunosurveillance. They infiltrate various solid tumors, and their numbers are correlated with good outcome. The function of NK cells extends their lytic capacities toward tumor cells ex...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.00683/full |
| _version_ | 1818591828078755840 |
|---|---|
| author | Meriem Messaoudene Meriem Messaoudene Alexandra Frazao Pierre Jean Gavlovsky Antoine Toubert Nicolas Dulphy Anne Caignard |
| author_facet | Meriem Messaoudene Meriem Messaoudene Alexandra Frazao Pierre Jean Gavlovsky Antoine Toubert Nicolas Dulphy Anne Caignard |
| author_sort | Meriem Messaoudene |
| collection | DOAJ |
| description | Natural killer (NK) cells are potent antitumor effectors, involved in hematological malignancies and solid tumor immunosurveillance. They infiltrate various solid tumors, and their numbers are correlated with good outcome. The function of NK cells extends their lytic capacities toward tumor cells expressing stress-induced ligands, through secretion of immunoregulatory cytokines, and interactions with other immune cells. Altered NK cell function due to tumor immune escape is frequent in advanced tumors; however, strategies to release the function of NK infiltrating tumors are emerging. Recent therapies targeting specific oncogenic mutations improved the treatment of cancer patients, but patients often relapse. The actual development consists in combined therapeutic strategies including agents targeting the proliferation of tumor cells and others restorating functional antitumor immune effectors for efficient and durable efficacy of anticancer treatment. In that context, we discuss the recent results of the literature to propose hypotheses concerning the potential use of NK cells, potent antitumor cytotoxic effectors, to design novel antitumor strategies. |
| first_indexed | 2024-12-16T10:18:38Z |
| format | Article |
| id | doaj.art-a019c89782114e5bb4803289f302aa01 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-16T10:18:38Z |
| publishDate | 2017-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a019c89782114e5bb4803289f302aa012022-12-21T22:35:22ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-06-01810.3389/fimmu.2017.00683264814Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor KillersMeriem Messaoudene0Meriem Messaoudene1Alexandra Frazao2Pierre Jean Gavlovsky3Antoine Toubert4Nicolas Dulphy5Anne Caignard6INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, FranceGustave Roussy Cancer Campus, Villejuif, FranceINSERM U1160, Institut Universitaire d’Hématologie, Hôpital Saint Louis, Paris, FranceINSERM U1160, Institut Universitaire d’Hématologie, Hôpital Saint Louis, Paris, FranceINSERM U1160, Institut Universitaire d’Hématologie, Hôpital Saint Louis, Paris, FranceINSERM U1160, Institut Universitaire d’Hématologie, Hôpital Saint Louis, Paris, FranceINSERM U1160, Institut Universitaire d’Hématologie, Hôpital Saint Louis, Paris, FranceNatural killer (NK) cells are potent antitumor effectors, involved in hematological malignancies and solid tumor immunosurveillance. They infiltrate various solid tumors, and their numbers are correlated with good outcome. The function of NK cells extends their lytic capacities toward tumor cells expressing stress-induced ligands, through secretion of immunoregulatory cytokines, and interactions with other immune cells. Altered NK cell function due to tumor immune escape is frequent in advanced tumors; however, strategies to release the function of NK infiltrating tumors are emerging. Recent therapies targeting specific oncogenic mutations improved the treatment of cancer patients, but patients often relapse. The actual development consists in combined therapeutic strategies including agents targeting the proliferation of tumor cells and others restorating functional antitumor immune effectors for efficient and durable efficacy of anticancer treatment. In that context, we discuss the recent results of the literature to propose hypotheses concerning the potential use of NK cells, potent antitumor cytotoxic effectors, to design novel antitumor strategies.http://journal.frontiersin.org/article/10.3389/fimmu.2017.00683/fulltumour immunosurveillancenatural killer ligandsimmune checkpoint inhibitorsBRAF inhibitorAMLMDSmelanoma |
| spellingShingle | Meriem Messaoudene Meriem Messaoudene Alexandra Frazao Pierre Jean Gavlovsky Antoine Toubert Nicolas Dulphy Anne Caignard Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers Frontiers in Immunology tumour immunosurveillance natural killer ligands immune checkpoint inhibitors BRAF inhibitor AMLMDS melanoma |
| title | Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers |
| title_full | Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers |
| title_fullStr | Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers |
| title_full_unstemmed | Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers |
| title_short | Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers |
| title_sort | patient s natural killer cells in the era of targeted therapies role for tumor killers |
| topic | tumour immunosurveillance natural killer ligands immune checkpoint inhibitors BRAF inhibitor AMLMDS melanoma |
| url | http://journal.frontiersin.org/article/10.3389/fimmu.2017.00683/full |
| work_keys_str_mv | AT meriemmessaoudene patientsnaturalkillercellsintheeraoftargetedtherapiesrolefortumorkillers AT meriemmessaoudene patientsnaturalkillercellsintheeraoftargetedtherapiesrolefortumorkillers AT alexandrafrazao patientsnaturalkillercellsintheeraoftargetedtherapiesrolefortumorkillers AT pierrejeangavlovsky patientsnaturalkillercellsintheeraoftargetedtherapiesrolefortumorkillers AT antoinetoubert patientsnaturalkillercellsintheeraoftargetedtherapiesrolefortumorkillers AT nicolasdulphy patientsnaturalkillercellsintheeraoftargetedtherapiesrolefortumorkillers AT annecaignard patientsnaturalkillercellsintheeraoftargetedtherapiesrolefortumorkillers |